|
Pharma industry, exporters to discuss PLI scheme for APIs with Korea to attract investment in 2026
|
|
Shardul Nautiyal, Mumbai
January 02 , 2025
|
|
|
In a major boost to the Indian bulk drugs industry, Indian pharma industry and exporters will discuss the production linked incentive (PLI) scheme for active pharmaceutical ingredients (APIs) with the Korean pharma industry at the upcoming 16th Edition of KOREA PHARM & BIO 2026 to attract Korean investment into India’s pharmaceutical and API sector. Besides this, opportunities for business partnerships and collaborations will also be discussed.
KOREA PHARM & BIO 2026 is one of the leading pharmaceutical and biotechnology exhibitions in the Republic of Korea to be held between March 31 and April 3, 2026 at KINTEX-II, Goyang-si, Gyeonggi-do, South Korea.
The Department of Pharmaceuticals (DoP) recently extended the timeline until January 16, 2026 for the pharma industry to submit their applications for support under the PLI scheme for bulk drugs to produce key ingredients of broad-spectrum carbapenem antibiotic meropenem and antiretroviral drug ritonavir. In November 2025, the DoP had announced the deadline or online submission of applications until December 26, 2025.
The DoP, under the PLI scheme for promotion of domestic manufacturing of critical key starting materials (KSMs), drug intermediates (DIs), and active pharmaceutical ingredients (APIs) in the country, in November, called for eligible firms to submit application for manufacturing of these products under the target segment of other chemical synthesis based KSMs, DIs, and APIs.
The PLI scheme for bulk drugs has been launched on March 20, 2020, with a financial outlay of Rs 6,940 crore for the period FY 2020-21 to FY 2029-30, aiming at promotion of domestic manufacturing of 41 identified bulk drugs to address their high import dependence.
In August, this year, the union ministry of chemicals and fertilisers, under which the DoP operates, stated that 32 companies have been selected for greenfield production through 48 projects involving 33 APIs/DIs/KSMs.
As a part of the mega-event, the Embassy of India, Seoul, in partnership with the event organizers, has planned to organize two or three focused round-table meetings focused on APIs, formulations, biologics etc on the sidelines of KOREA PHARM & BIO 2026.
B2B meetings have also been proposed between Indian exporters and Korean buyers, particularly involving mid-level procurement and sourcing professionals. To facilitate effective matchmaking, the Pharmaceuticals Export Promotion Council of India (Pharmexcil) has urged its member companies to provide a brief company profile along with details of the products manufactured or exported, which will be shared with the prospective Korean counterparts.
The event is being organised by Kyungyong Exhibition Corporation with support from Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), Ministry of Food and Drug Safety (MFDS), Korea Drug Research Association (KDRA), and Korea Pharmaceutical Traders Association (KPTA).
Exhibition profile includes APIs, finished dosage, intermediates, excipients, formulation, functional ingredients, fine chemicals, natural extracts, biopharmaceuticals, biosimilars, bio services & biotechnology, bio cluster and bio logistics.
It also includes contract services and outsourcing such as contract manufacturing organisation (CMO), contract research organisation (CRO), pre clinical trials, clinical trials (Phase I-?), bioequivalence test, clinical data management, analytical & lab service, bio service and other outsourcing, natural ingredients, functional ingredients, health supplements, pharmaceutical bio laboratory and analytical equipment, pharmaceutical bio consulting, pharmaceutical bio IT service, investor relations consulting, intellectual property (IP), patent law service and pharmaceutical bio logistics & distribution.
Smart healthcare includes personalized medicine, digital therapeutics, next generation diagnosis and prevention, telemedicine, advanced genetic research, high-tech imaging diagnosis, bio-organization reconstruction and wearable medical devices.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|